Myriad Genetics logo
Myriad Genetics
MYGN | NASDAQ
Chart Builder DCF Calculator
$5.57
-$0.09 (-1.59%)
At close: Nov 16, 2026, 4:00 PM ET
$5.57
$0.00 (0.00%)
After-hours: Nov 16, 2026, 5:56 PM ET

Myriad Genetics Company Profile

Company profile explained

Company Profile

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Key Executives

Name Position
Samraat S. Raha President, Chief Executive Officer & Director
Benjamin R. Wheeler Chief Financial Officer & Principal Accounting Officer
Jennifer L. Fox Chief Legal Officer
Mark S. Verratti Chief Operating Officer
Raj Jampa Chief Technology Officer
Shereen Solaiman Chief People Officer
Brian Donnelly Chief Commercial Officer
Dale Muzzey Chief Scientific Officer
Matthew Scalo Senior Vice President of Investor Relations
Patrick Burke Executive Vice President of Corporate & Business Development
Paul J. Diaz Consultant

Latest SEC Filings

Date Type Title
Oct 27, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Oct 20, 2026 8-K Current Report
Oct 09, 2026 8-K Current Report
Sep 22, 2026 4 Filing
Sep 18, 2026 4 Filing
Sep 17, 2026 4 Filing
Sep 17, 2026 3 Filing
Sep 16, 2026 8-K Current Report
Sep 08, 2026 4 Filing
Sep 04, 2026 SC 13G Statement of acquisition of beneficial ownership b...
View All SEC Filings ➞
Myriad Genetics
Myriad Genetics logo
Country United States
IPO Date Oct 6, 1995
Industry Medical - Diagnostics & Research
Sector Healthcare
Employees 2,700
CEO Samraat S. Raha

Contact Details

322 North 2200 West Salt Lake City, Utah 84116 United States

Stock Details

Ticker Symbol MYGN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000899923
CUSIP Number 62855J104
ISIN Number US62855J1043
SIC Code 2835

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.